Florian Naudet

It is a 236 patient trial while in the registry it is planned to be a 80 patient trials. Primary outcome was HDRS and is now smoking cessation. The date in the ethics committee seems to be 2022 (No. 2022-048) while it was 2023-02-20.
OFC, it needs double check.

www.chictr.org.cn/showprojEN.h...

This 👇sets a very high bar for replying a letter to the editor. Maybe the scientifical publishing system has not entirely ceased to be?

An exemple of nice and smart response by Andreas M. Schmitt, Cathrine Axfors, David Moher, Steven N. Goodman, John P. A. Ioannidis and Lars G. Hemkens. "We think that the harm signal for hydroxychloroquine has substantial evidence."

www.nature.com/articles/s41...

It can be both in my opinion. What makes the difference is the intention which id’s of course always difficult to know.

"Honest yet unacceptable research practices: when research becomes a health risk"

bmjopen.bmj.com/content/15/6...

👍

International Congress on Peer Review and Scientific Publication Enhancing the quality and credibility of science.

Don’t miss

Use of an #OpenScience Checklist & Findings Reproducibility

from ‪@mariskaleeflang.bsky.social‬ @ingestegeman.bsky.social‬
‪@floriannaudet.bsky.social‬ ‪@mlrethlefsen.bsky.social‬
‪@amsterdamumc.bsky.social‬

on day 3!

Register at peerreviewcongress.org!

@bmj.com @jama.com

Congrats, Mathieu Repiquet 👏! The hunt is on — and the pâté is going to be excellent 😄.

Mathieu is definitely someone to watch 🔍. He co-constructed his entire research project with us, submitted it to his doctoral school 🎓, applied to two competitive programs — and secured one of them 🏆.

After working closely with him for the past 4–5 months during his Master’s 📝, I can confidently say — it’s going to be high-impact, high-caliber stuff 💥. But also handled with the intelligence and nuance that Mathieu brings (and that I clearly don’t — as this message illustrates 😅).

Which brings me to this great news 🥳: together with Bruno Falissard and Caroline Barry, I’m thrilled to be supervising, starting next year, a PhD student from that second category of hunters: Mathieu Repiquet 🧑‍🔬.

And let’s be honest — both types help us better understand what evidence-based medicine is really about. And clearly, that kind of research spreads pâté far and wide 😋.

In evidence-based medicine 📚, it's pretty much the same: there are researchers who go after quackery within conventional medicine 💉, and others who take a closer look at quackery in alternative therapies 🌿.

Then there are other hunters who are perfectly happy to find an old wounded hare 🐇 by the roadside and finish it off with a machine gun 🔫.

But hey, it takes all sorts to make a world — and at the end of the day, both end up eating pâté 🥩. Some might even come home empty-handed 🤷.

Important message, but terrible metaphor… 🫣

There are hunters who enjoy wandering through vast, wild forests 🌲, spotting majestic stags 🦌, carefully adjusting their aim 🎯, and savoring the victory of a clean shot — after withstanding the charge of the herd.

...and they have no clue whom they are talking to. 🤦🏼‍♀️

Many thanks 🙏

Excellent and important paper on the efficacy and safety of Esketamine 👇

By the way, when looking at the email adress, it is not from @natureportfolio.nature.com scientific reports...

... Submission process: Kindly submit manuscript as an attachment to this email only.
Thanks & Regards,
Editorial Office
Scientific Reports Journal"

We would like to know your time and interest in submitting of the preprint to our journal. Early submission benefits you to get published your manuscript within 30 days with a world class peer-review process with special discount on publication charges...

“Efficacy and safety of esketamine for treatment resistant depression: registered report [...] Meta-analysis of Randomized, Double-Blind, Placebo-Controlled Trials" is much-admired and very impressive and they have immense relevance to the scope and mandate of the upcoming issue of our journal...

And by the way, highly recommended by PREDATORY JOURNALS... 😂 Here is the mail that I received today following the preprint.

"Dear Dr.Florian Naudet,...

Efficacy and safety of esketamine for treatment resistant depression: registered report for a Systematic Review with an Individual Patient Data Meta-analysis of Randomized, Double-Blind, Placebo-Contr... Background In 2019, the FDA and EMA approved intranasal esketamine for treatment resistant depression (TRD). The current study re–evaluated its efficacy and safety. Methods This registered report pres...

Preprint 👇 and soon a 🧵 about the results :)

Programme hospitalier de recherche clinique - PHRC – Ministère du Travail, de la Santé, des Solidarités et des Familles Le programme hospitalier de recherche clinique (PHRC) couvre le champ de recherche clinique qui a pour objet l'évaluation de la sécurité, de la tolérance, de la faisabilité ou de l'efficacité des…

And super happy to deliver our job done with our funding from the 🇫🇷 DGOS (PHRC).

It was so cool to work with all this super team.

Claude Pellen, Liviu A Fodor, Chiara Gastaldon, Corrado Barbui, Erick Turner, Estelle Le Pabic, and @ioanaacristea.bsky.social

We are not only honored to be considered by BMC Medicine but also proud to contribute to the field through this rigorous and transparent format.

Given the importance of the topic, we might have pursued a journal with greater notoriety—but we prioritized BMC Medicine for its rigorous publication standards, as it is one of the few general medical journals—if not the only one—to offer registered reports.

We hope that, given our close adherence to the preregistered plans and our commitment to transparency, BMC Medicine will consider this Stage 2 Registered Report for publication.

While we are unable to publicly share the individual participant data due to its sensitive nature, we include clear guidance on how this data can be accessed through the YODA Project (at Yale University).